Thrivent Financial for Lutherans Purchases 107,818 Shares of Zoetis Inc. $ZTS

Thrivent Financial for Lutherans lifted its position in shares of Zoetis Inc. (NYSE:ZTS) by 311.3% in the fourth quarter, HoldingsChannel.com reports. The firm owned 142,457 shares of the company’s stock after purchasing an additional 107,818 shares during the period. Thrivent Financial for Lutherans’ holdings in Zoetis were worth $17,925,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. New York Life Investment Management LLC lifted its holdings in Zoetis by 1.3% in the 4th quarter. New York Life Investment Management LLC now owns 65,904 shares of the company’s stock worth $8,292,000 after buying an additional 862 shares during the period. Pinnacle Associates Ltd. increased its stake in shares of Zoetis by 4.6% during the fourth quarter. Pinnacle Associates Ltd. now owns 19,442 shares of the company’s stock valued at $2,446,000 after buying an additional 859 shares during the period. Baader Bank Aktiengesellschaft raised its holdings in shares of Zoetis by 28.4% during the fourth quarter. Baader Bank Aktiengesellschaft now owns 34,464 shares of the company’s stock valued at $4,273,000 after acquiring an additional 7,630 shares in the last quarter. Allworth Financial LP raised its holdings in shares of Zoetis by 32.2% during the fourth quarter. Allworth Financial LP now owns 62,429 shares of the company’s stock valued at $7,855,000 after acquiring an additional 15,199 shares in the last quarter. Finally, Grey Ledge Advisors LLC lifted its stake in Zoetis by 38.3% in the fourth quarter. Grey Ledge Advisors LLC now owns 10,223 shares of the company’s stock worth $1,286,000 after acquiring an additional 2,833 shares during the period. 92.80% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the stock. Stifel Nicolaus set a $105.00 target price on shares of Zoetis in a research note on Friday, May 8th. Weiss Ratings downgraded shares of Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, March 27th. Citigroup lowered their price objective on shares of Zoetis from $145.00 to $112.00 and set a “buy” rating for the company in a report on Monday. JPMorgan Chase & Co. cut their price objective on Zoetis from $190.00 to $130.00 and set an “overweight” rating on the stock in a research report on Friday, May 8th. Finally, William Blair reiterated an “outperform” rating on shares of Zoetis in a report on Monday, March 2nd. Seven equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Zoetis currently has a consensus rating of “Hold” and a consensus price target of $134.75.

Insider Buying and Selling

In related news, Director Paul Bisaro acquired 2,000 shares of Zoetis stock in a transaction dated Wednesday, May 13th. The stock was purchased at an average cost of $75.88 per share, for a total transaction of $151,760.00. Following the purchase, the director directly owned 27,862 shares of the company’s stock, valued at approximately $2,114,168.56. This trade represents a 7.73% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Frank A. Damelio purchased 6,650 shares of Zoetis stock in a transaction on Wednesday, May 13th. The stock was bought at an average price of $75.39 per share, with a total value of $501,343.50. Following the transaction, the director owned 21,458 shares of the company’s stock, valued at approximately $1,617,718.62. This represents a 44.91% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders bought 11,650 shares of company stock valued at $886,384 over the last 90 days. Company insiders own 0.22% of the company’s stock.

Zoetis Stock Up 4.8%

NYSE:ZTS opened at $77.78 on Tuesday. The firm has a market cap of $32.61 billion, a P/E ratio of 12.90, a P/E/G ratio of 1.21 and a beta of 0.87. The company has a debt-to-equity ratio of 2.80, a quick ratio of 1.91 and a current ratio of 3.15. Zoetis Inc. has a fifty-two week low of $72.38 and a fifty-two week high of $172.23. The firm has a 50-day simple moving average of $111.39 and a two-hundred day simple moving average of $120.28.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Thursday, May 7th. The company reported $1.53 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.60 by ($0.07). The business had revenue of $2.26 billion during the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The business’s revenue was up 2.9% compared to the same quarter last year. During the same period last year, the company posted $1.48 earnings per share. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Analysts predict that Zoetis Inc. will post 6.91 earnings per share for the current fiscal year.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.